865 related articles for article (PubMed ID: 9181459)
1. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
9. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
11. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
13. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
Dummer R; Müller W; Nestle F; Wiede J; Dues J; Lechner W; Haubitz I; Wolf W; Bill E; Burg G
Cancer; 1991 May; 67(9):2300-4. PubMed ID: 1901514
[TBL] [Abstract][Full Text] [Related]
14. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
17. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
[TBL] [Abstract][Full Text] [Related]
18. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
Hänninen EL; Knüver-Hopf J; Atzpodien J
Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]